Late presentation and transmitted drug resistance mutations in new HIV-1 diagnoses in Detroit

International Journal of Infectious Diseases

Volumn 15, Issue 11, 2011, Pages

  Huaman, Moises A ^a   Aguilar, Javier ^a,b   Baxa, Dwayne ^b   Golembieski, Alicia ^b   Brar, Indira ^a,b   Markowitz, Norman ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

Antiretroviral resistance; Epidemiology; HIV; Resistance mutations

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE; NUCLEOSIDE REVERSE TRANSCRIPTASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUTATION RATE; PREVALENCE; RETROSPECTIVE STUDY; TRANSMITTED DRUG RESISTANCE MUTATION; UNITED STATES; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 80054949926     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.06.007     Document Type: Article

References (29)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011.
2. Althoff K.N., Gange S.J., Klein M.B., Brooks J.T., Hogg R.S., Bosch R.J., et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010, 50:1512-15120.
3. Girardi E., Sabin C.A., Monforte A.D. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007, 46(Suppl 1):S3-S8.
4. Quarterly HIV/AIDS analysis. Lansing, MI: Michigan Department of Community Health; 2011.
5. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003, 34:76-83. CASCADE Collaboration.
6. Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2009, p. 1-161.
7. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS; 2010, 24:1203-12.
8. Sax P.E., Islam R., Walensky R.P., Losina E., Weinstein M.C., Goldie S.J., et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005, 41:1316-1323.
9. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47:266-285.
10. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas J.M., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189:2174-2180.
11. Centers for Disease Control Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41(RR-17):1-19.
12. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4:e4724.
13. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42:1608-1618.
14. Gifford R.J., Liu T.F., Rhee S.Y., Kiuchi M., Hue S., Pillay D., et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009, 25:1197-1198.
15. SPREAD programme Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22:625-635.
16. Jayaraman G.C., Archibald C.P., Kim J., Rekart M.L., Singh A.E., Harmen S., et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006, 42:86-90.
17. HIV-1 strain and primary drug resistance in Canada: surveillance report to March 31, 2005. Ottawa, Canada: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2006.
18. Ross L., Lim M.L., Liao Q., Wine B., Rodriguez A.E., Weinberg W., et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007, 8:1-8.
19. Jain V., Liegler T., Vittinghoff E., Hartogensis W., Bacchetti P., Poole L., et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010, 5:e15510.
20. Boyd A.C., Herzberg E.M., Marshall M.M., Lamparello N.A., De Leon M.A., Porter A., et al. Antiretroviral drug resistance among treatment-naive HIV-1-infected persons in Washington, D.C. AIDS Patient Care STDS 2008, 22:445-448.
21. Colonno R.J., Thiry A., Limoli K., Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003, 47:1324-1333.
22. Marcelin A.G., Chazallon C., Gerard L., Saidi Y., Aboulker J.P., Girard P.M., et al. External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients. J Acquir Immune Defic Syndr 2006, 42:127-128.
23. Alam S.J., Romero-Severson E., Kim J.H., Emond G., Koopman J.S. Dynamic sex roles among men who have sex with men and transmissions from primary HIV infection. Epidemiology 2003, 21:669-675.
24. Gandhi R.T., Wurcel A., Rosenberg E.S., Johnston M.N., Hellmann N., Bates M., et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003, 37:1693-1698.
25. Cong M.E., Heneine W., Garcia-Lerma J.G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007, 81:3037-3041.
26. Briones C., Domingo E. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev 2008, 10:93-109.
27. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008, 5:e158.
28. Eron J.J., Young B., Cooper D.A., Youle M., Dejesus E., Andrade-Villanueva J., et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407.
29. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365.